Oncternal Therapeutics ONCT shares are trading lower on Wednesday after the company announced an increase in its previously announced bought deal offering to 7.25 million shares at $3.10 per share.
Oncternal Therapeutics is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. Its product pipeline includes Cirmtuzumab, TK216, and ROR1 CAR-T.
Oncternal Therapeutics shares were trading down 29.95% at $2.90 at last check Wednesday. The stock has a 52-week range between $6.28 and $1.49.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
